top of page

The Potential Role of Amyloid Beta Peptides Concussion Biomarkers Reported



Increased levels of circulating amyloid beta (abeta) - 40 and -42 peptides are often increased after concussion. As such, these peptides are promising blood biomarkers of post-concussive events and neurological damage. Concussion-like symptoms are also associated with increased abeta in peripheral blood after blast exposure devoid of a clinically defined injury. A recently published review and opinion article highlights recent work describing abeta elevation in peripheral blood among persons with probable or diagnosed concussion. The authors propose utility of abeta to augment clinical examination or provide rationale for continuous, post-event monitoring.


These studies were originally featured in

Frontiers Neurology, Neurotrauma - Insights in Neurotrauma: 2021


“Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion”


Angela M Boutté, Ph.D., Bharani Thangavelu, Ph.D., and John Anagli, Ph.D.




Aries Biotech is a neurological disease and dementia biomarker consulting company.


To learn how we can augment your needs, visit Aries Biotech at https://www.ariesbiotechnologies.org

18 views0 comments

Recent Posts

See All

Dr. Boutte Joins PRECISE-TBI Biomarker Working Group

Dr. Boutte Joins PRECISE-TBI Biomarker Working Group Aries Biotech extends gratitude to the PRECISE-TBI team, for inviting Dr. Angela Boutte, the founder of Aries Biotech, to participate in the precli

Dr. Boutte of Aries Biotech Consults for BBCETC

Dr. Boutte of Aries Biotech is honored to serve as a consultant for BBC Entrepreneurial Training & Consulting (BBCetc).  The BBCetc (https://bbcetc.com/) is nationally recognized for successfully help

Thank you - Alzheimer’s Research UK!

Aries Biotech extends gratitude to the Alzheimer’s Research UK team, for inviting Dr. Angela Boutte, the founder of Aries Biotech, as a contributing reviewer and panelist. Through partnerships with th

bottom of page